SAN JOSE, Calif.--(BUSINESS WIRE)--HemoSense, Inc. (AMEX:HEM) today announced that it has received medical device licenses from Health Canada to market its INRatio® PT/INR monitoring system for point-of-care and patient self testing in Canada. HemoSense expects to formalize distribution relationships during the current fiscal quarter, and begin selling INRatio within Canada in the coming months.
